| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | JW-74 | CTRPv2 | pan-cancer | AAC | 0.049 | 0.3 |
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | elocalcitol | CTRPv2 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | DBeQ | CTRPv2 | pan-cancer | AAC | 0.039 | 0.3 |
| mRNA | pifithrin-alpha | CTRPv2 | pan-cancer | AAC | 0.039 | 0.3 |
| mRNA | R428 | CTRPv2 | pan-cancer | AAC | 0.045 | 0.3 |
| mRNA | neopeltolide | CTRPv2 | pan-cancer | AAC | -0.076 | 0.3 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |